![]() |
Name |
bipolarisorokin H
|
Molecular Formula | C17H24O3 | |
IUPAC Name* |
3-(6-formyl-1,7-dimethyl-4-propan-2-yl-8-bicyclo[3.2.1]oct-6-enyl)prop-2-enoicacid
|
|
SMILES |
CC1=C(C=O)C2C(C(C)C)CCC1(C)C2C=CC(=O)O
|
|
InChI |
InChI=1S/C17H24O3/c1-10(2)12-7-8-17(4)11(3)13(9-18)16(12)14(17)5-6-15(19)20/h5-6,9-10,12,14,16H,7-8H2,1-4H3,(H,19,20)/b6-5+/t12-,14+,16-,17+/m1/s1
|
|
InChIKey |
AWHMDLAWUMJQNJ-FRBCAHLNSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 276.38 | ALogp: | 3.5 |
HBD: | 1 | HBA: | 2 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 54.4 | Aromatic Rings: | 2 |
Heavy Atoms: | 20 | QED Weighted: | 0.618 |
Caco-2 Permeability: | -4.954 | MDCK Permeability: | 0.00001740 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.007 | 20% Bioavailability (F20%): | 0.004 |
30% Bioavailability (F30%): | 0.001 |
Blood-Brain-Barrier Penetration (BBB): | 0.33 | Plasma Protein Binding (PPB): | 90.42% |
Volume Distribution (VD): | 0.509 | Fu: | 4.70% |
CYP1A2-inhibitor: | 0.022 | CYP1A2-substrate: | 0.351 |
CYP2C19-inhibitor: | 0.02 | CYP2C19-substrate: | 0.879 |
CYP2C9-inhibitor: | 0.035 | CYP2C9-substrate: | 0.962 |
CYP2D6-inhibitor: | 0.003 | CYP2D6-substrate: | 0.131 |
CYP3A4-inhibitor: | 0.147 | CYP3A4-substrate: | 0.366 |
Clearance (CL): | 5.004 | Half-life (T1/2): | 0.596 |
hERG Blockers: | 0.001 | Human Hepatotoxicity (H-HT): | 0.069 |
Drug-inuced Liver Injury (DILI): | 0.511 | AMES Toxicity: | 0.034 |
Rat Oral Acute Toxicity: | 0.357 | Maximum Recommended Daily Dose: | 0.062 |
Skin Sensitization: | 0.11 | Carcinogencity: | 0.88 |
Eye Corrosion: | 0.65 | Eye Irritation: | 0.126 |
Respiratory Toxicity: | 0.984 |